LB773 Treating pemphigus vulgaris (PV) and foliaceus (PF) by inhibiting the neonatal Fc receptor: Phase 2 multicentre open-label trial with efgartigimod

Authors :: Éva Remenyik
Pascal Joly
H. de Haard
B. Didona
Zsuzsanna Bata-Csorgo
Peter Verheesen
Enno Schmidt
Maria-Elisabeth Goebeler
C. De Simone
E S Ward
Wim Parys
Johanna Stoevesandt
N. Reznichenko
P. Dupuy
Source :: Journal of Investigative Dermatology. 141:B16
Publication Year :: 2021
Publisher :: Elsevier BV, 2021.

Subjects :: Neonatal Fc receptor
business.industry
Pemphigus vulgaris
medicine
Cell Biology
Dermatology
Open label
Pharmacology
medicine.disease
business
Molecular Biology
Biochemistry

Full Text Access

Tools